NERVIANO, Italy & MILAN--(BUSINESS WIRE)--Nerviano Medical Sciences S.r.l. (NMS), a clinical-stage biotechnology company member of NMS group, announced the signing of a license agreement with ...
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its ...
[Reference] Araris Biotech AG Announces Research Collaboration and Option to License Agreement with Chugai Pharmaceutical Co. to Develop Next-Generation ADCs Using Araris’ AraLinQᵀᴹ technology (Press ...
Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...
DUBLIN--(BUSINESS WIRE)--The "Antibody Drug Conjugate Market Industry Trends and Global Forecasts to 2035, by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens and Key ...
DAEJEON, South Korea and NORTH BETHESDA, Md., Oct. 31, 2025 (GLOBE NEWSWIRE) -- IntoCell Inc. (KOSDAQ: 287840), a biotechnology company developing next-generation payload and linker technologies for ...
PALO ALTO, CA, UNITED STATES, August 13, 2025 / EINPresswire.com / -- Baylink Biosciences, a biotechnology company pioneering next-generation antibody-drug conjugate (ADC) technologies, today ...
Chugai Pharma and Araris Biotech ink license agreement for Araris' linker-payload ADC technology AraLinQ: Tokyo Wednesday, February 11, 2026, 11:00 Hrs [IST] Chugai Pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results